Abstract
35 High pathologic complete remission rate with liposome-encapsulated doxorubicin + paclitaxel + trastuzumab as primary treatment in HER-2 positive operable breast cancer: clinical experience
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have